Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NEOM GO GO!! b 0.004 / a 0.0042 !!!!
$NEOM bid 0.0038 / ask 0.0039!!! $0.10 coming!
$NEOM Big Buyers!!!!
$NEOM 0.0037!!!!!!!!!!! GO TO $0.10!!!
$NEOM You Prepare for a strong rebound. They have been accumulating for several days. In $NEOM will eventually buyout. That is known. IMO.
$NEOM In Most Read Boards Today!!!!
FYI $NEOM is traded with accumulation. STRONG ACCUMULATION...
$NEOM Patrick Soon-Shiong know this. Buyout? $0.05 per share?
$NEOM $0.01? $0.02? $0.30? $1?
$NEOM Dr. Patrick Soon-Shiong Buying Shares!!!!!
$NEOM Today go to $0.01!
$ZLCS Are Seasonally Ripe To Go Up In the Next Five Weeks
http://barchart.com/headlines/story.php?id=7836180
$ZLCS "Buy confirmed" Yesterday a White Candlestick was formed.
http://americanbulls.com/StockPage.asp?CompanyTicker=ZLCS&MarketTicker=NASD&TYP=S
Good Morning Orions!
$ZLCS It is speculated that they have an offer of $10 per share by the company! Z160, Z944, Prednisporin, Exalgo, CHTs System with Novartis Oncology Collaboration! I will be very happy if that happens. Good luck! Your luck will be mine.
$ZLCS was at $13.65 in FEB 06!!!! UNDERVALUED!!!!
$ZLCS +11.67! Strong Volume! Close in $0.73-$0.74!
$ZLCS Novartis clinical trials (cancer) with combination of drugs (cHTS) link:
http://clinicaltrials.gov/ct2/results?term=novartis+cancer+combination&Search=Search
$ZLCS From YMB about Zalicus and Novartis clinical trials:
Just a few that have recently been updated and are fairly new since the collaboration started. Looks like the Novartis partnership is alive and well. Too many to list here. The list goes on and on......
Just look at clinical trials(dot)gov and you will find a boat load of combination drug trials for cancer and there genotypes. This certainly lines up to what Mr. Corrigan referred to at the ASCO-NCI-EORTC Molecular Markers meeting.
Not yet open to enrollment-6/2012- A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER
Currently recruiting-4/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
10/2010- A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
5/2012- A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
9/2011-An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor?) in Combination With BEZ235 in Patients With Advanced Solid Tumors
6/2010-A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.
5/2012-A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer
$ZLCS Nice call bro! PT $1.5 or $2 The same of $SVNT!
$ZLCS 11.85% Go to $1 or GAP in $1.32!
I don't look at image...
$ZLCS +7.43% ALERT! ALERT! Next stop $1!!!!
$ZLCS Pfizer conection with Mark Versavel. Nice! Pfizer buyout??????
$ZLCS On Sep., Canaccord Genuity Reiterates a 'Buy' on Zalicus PT $3
http://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Reiterates+a+Buy+on+Zalicus+(ZLCS)%3B+Focus+Shifts/7717317.html
$ZLCS Golden cross to $1 or $2! Good news comming!
$ZLCS Nice volume. UP UP UP!
$ZLCS Up $0.64 +6.67%
Yesterday I added 50k shares. I have 300k shares in Zalicus. I'm buying up 500k shares.
link clinical trials Novartis + Zalicus with cHTS combination system:
http://clinicaltrials.gov/ct2/results?term=novartis+cancer+combination&Search=Search
CombinatoRx (ZALICUS) teams up with Novartis
May 6, 2009 08:04
CombinatoRx Inc. announced an oncology collaboration with Novartis AG, the Swiss drug giant, that will yield CombinatoRx an up-front payment of $4 million.
CombinatoRx is headquartered in Cambridge, where Novartis has a global research unit. A Globe story from last fall noted that Novartis has roughly 2,000 employees in Cambridge.
"The collaboration will explore combination effects in cell lines representing a broad spectrum of cancers to provide a robust and systematic understanding of combination therapy opportunities," CombinatoRx said in a press release.
The release added: "Under the agreement, CombinatoRx will receive a $4 million up-front payment and funding for research support for two years. In addition, for each combination advanced to the market from the collaboration, CombinatoRx is eligible to receive up to $58 million in clinical, regulatory, and commercial milestones."
Alexis Borisy, president and chief executive of CombinatoRx, said in a statement, "Our alliance with Novartis further supports our business strategy of leveraging the CombinatoRx drug discovery platform while retaining important product rights."
Source: http://www.boston.com/business/ticker/2009/05/combinatorx_tea.html
For Remember: The cancer cure will be a combination of compounds. Novartis knows that. For this reason, He is collaborating with cHTS platform of Zalicus.
I bet you that Oppenheimer will lead to $5 before March.
They are very good. They are my favorite analysts.
$ZLCS Oppenheimer has to be buying more of 10MM shares. You look at the chart.
$ZLCS Institutional investors are seeing an opportunity in Zalicus. For that reason, you will see accumulation in Zalicus.
You're welcome. I'll try to make a post with all the information.
$ZLCS My contacts tell me that Phase II Z944 begin in January. The results will have them before the end of the year.
PS: Very good results in phase I. Z944
IMHO.
Re-post: From YMB about Zalicus and Novartis clinical trials :
Just a few that have recently been updated and are fairly new since the collaboration started. Looks like the Novartis partnership is alive and well. Too many to list here. The list goes on and on......
Just look at clinical trials(dot)gov and you will find a boat load of combination drug trials for cancer and there genotypes. This certainly lines up to what Mr. Corrigan referred to at the ASCO-NCI-EORTC Molecular Markers meeting.
Not yet open to enrollment-6/2012- A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER
Currently recruiting-4/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
10/2010- A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
5/2012- A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
9/2011-An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor?) in Combination With BEZ235 in Patients With Advanced Solid Tumors
6/2010-A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.
5/2012-A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer